Atriance blev anvendt i to hovedundersøgelser af patienter med T- ALL og T- LBL, hos hvem en eller flere typer kræftbehandling var holdt op med at virke.
Atriance has been studied in two main studies of patients with T-ALL and T-LBL who had stopped responding to one or more previous anticancer treatments.